BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38296676)

  • 1. Tumoural Pellino-1 expression and Pellino-1-expressive cytotoxic T-cells are associated with poor prognosis in diffuse large B-cell lymphoma.
    Shin SJ; Ko J; Hwang HS; Huh J; Lee CW; Lee JK; Go H
    Pathology; 2024 Apr; 56(3):374-381. PubMed ID: 38296676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse large B-cell lymphoma: the significance of CD8
    Zhu Q; Yang Y; Chen K; Zhang Q; Huang Y; Jian S
    J Transl Med; 2024 Feb; 22(1):174. PubMed ID: 38369502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher densities of Foxp3
    Yeong J; Thike AA; Lim JC; Lee B; Li H; Wong SC; Hue SS; Tan PH; Iqbal J
    Breast Cancer Res Treat; 2017 May; 163(1):21-35. PubMed ID: 28233108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High tumoral PD-L1 expression and low PD-1
    Kim S; Nam SJ; Park C; Kwon D; Yim J; Song SG; Ock CY; Kim YA; Park SH; Kim TM; Jeon YK
    Oncoimmunology; 2019; 8(9):e1626653. PubMed ID: 31428525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed cell death-ligand 1 (PD-L1)
    Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
    Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma.
    Yu T; Xu-Monette ZY; Lagoo A; Shuai W; Wang B; Neff J; Carrillo LF; Carlsen ED; Pina-Oviedo S; Young KH
    Front Immunol; 2024; 15():1335689. PubMed ID: 38348048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The presence of tumour-infiltrating lymphocytes (TILs) and the ratios between different subsets serve as prognostic factors in advanced hypopharyngeal squamous cell carcinoma.
    Wang J; Tian S; Sun J; Zhang J; Lin L; Hu C
    BMC Cancer; 2020 Aug; 20(1):731. PubMed ID: 32758195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prognostic Value of FoxP3+ Tumour-Infiltrating Lymphocytes in Rectal Cancer Depends on Immune Phenotypes Defined by CD8+ Cytotoxic T Cell Density.
    Schnellhardt S; Hirneth J; Büttner-Herold M; Daniel C; Haderlein M; Hartmann A; Fietkau R; Distel L
    Front Immunol; 2022; 13():781222. PubMed ID: 35140715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
    Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
    APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration.
    Liu S; Foulkes WD; Leung S; Gao D; Lau S; Kos Z; Nielsen TO
    Breast Cancer Res; 2014 Sep; 16(5):432. PubMed ID: 25193543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma.
    Hasselblom S; Sigurdadottir M; Hansson U; Nilsson-Ehle H; Ridell B; Andersson PO
    Br J Haematol; 2007 May; 137(4):364-73. PubMed ID: 17456059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast.
    Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
    BMC Cancer; 2021 Mar; 21(1):286. PubMed ID: 33726701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.
    Xu T; Chai J; Wang K; Jia Q; Liu Y; Wang Y; Xu J; Yu K; Zhao D; Ma J; Fan L; Yan Q; Guo S; Chen G; Chen Q; Xiao H; Liu F; Qi C; Liang R; Li M; Wang Z
    Front Oncol; 2021; 11():638154. PubMed ID: 34221962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
    Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
    Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation study of PD-L1, CD4, CD8, and PD-1 in primary diffuse large B-cell lymphoma of the central nervous system.
    Liu B; Yan S; Li S; Zhang Q; Yang M; Yang L; Ma J; Li X
    Pathol Res Pract; 2022 Nov; 239():154008. PubMed ID: 36183436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3
    Zhang T; Ren T; Song Z; Zhao J; Jiao L; Zhang Z; He J; Liu X; Qiu L; Li L; Zhou S; Meng B; Zhai Q; Ren X; Qian Z; Wang X; Zhang H
    J Immunol Res; 2020; 2020():6968595. PubMed ID: 33178839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effector memory cytotoxic CD3
    Sun X; Zhai J; Sun B; Parra ER; Jiang M; Ma W; Wang J; Kang AM; Kannan K; Pandurengan R; Zhang S; Solis LM; Haymaker CL; Raso MG; Mendoza Perez J; Sahin AA; Wistuba II; Yam C; Litton JK; Yang F
    Mod Pathol; 2022 May; 35(5):601-608. PubMed ID: 34839351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
    Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
    Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-Infiltrating CD20
    Suárez-Sánchez FJ; Lequerica-Fernández P; Rodrigo JP; Hermida-Prado F; Suárez-Canto J; Rodríguez-Santamarta T; Domínguez-Iglesias F; García-Pedrero JM; de Vicente JC
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33494389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.